Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age

NCT01702428 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

5016

Enrollment

INDUSTRY

Sponsor class

Conditions

Rubella
Measles
Mumps

Interventions

BIOLOGICAL: Priorix
BIOLOGICAL: M-M-R II
BIOLOGICAL: Varivax
BIOLOGICAL: Havrix
BIOLOGICAL: Prevnar 13

Sponsor

GlaxoSmithKline